Artificial cells with emphasis on cell encapsulation of genetically engineered cells

Artificial Organs

Volumn 22, Issue 11, 1998, Pages 958-965

  Chang, Thomas Ming Swi ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b Artificial Cells and Organs Research Centre

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Artificial cells; Encapsulation; Genetically engineered cells; Microencapsulation; Urea removal; Uremia

Indexed keywords

ARTIFICIAL CELLS; DRUG DELIVERY; ENZYMES; GENE THERAPY; GENETIC ENGINEERING; MEDICAL APPLICATIONS; METABOLISM; UREA;

ARTIFICIAL CELL; BIOTECHNOLOGICAL APPLICATIONS; CELL ENCAPSULATIONS; CELL-BE; CELL/B.E; CELL/BE; CLINICAL TRIAL; GENETICALLY ENGINEERED CELL; UREA REMOVALS; UREMIA;

CYTOLOGY;

BLOOD SUBSTITUTE; CATALASE; ENZYME; HEMOGLOBIN DERIVATIVE; POLYMER; SUPEROXIDE DISMUTASE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTIFICIAL ORGAN; CELL; CLINICAL TRIAL; DRUG CONJUGATION; ENCAPSULATION; ENZYME DEFICIENCY; ERYTHROCYTE; GENE THERAPY; GENETIC ENGINEERING; HEMOPERFUSION; HUMAN; IMPLANTATION; INBORN ERROR OF METABOLISM; KIDNEY FAILURE; MICROORGANISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; UREMIA;

ANIMALIA;

EID: 0031729914     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1998.06243.x     Document Type: Review

References (63)

1. Kolff WJ. New ways of treating uraemia: The artificial kidney, peritoneal lavage, intestinal lavage. Portman Square, London: J & A Churchill, 1947.
2. Chang TMS. Hemoglobin corpuscles. Research Report for Honors Physiology, Medical Library, McGill University, 1957. Reprinted as 30 anniversary in artificial red blood cells research. J Diomater Anif Cells Artif Organs 1988;16:l-9.
3. Chang TMS. Semipermeable microcapsules. Science 1964;146: 524-5.
4. Chang TMS, Macintosh FC, Mason SG. Semipermeable aqueous microcapsules: I. Preparation and properties. Can J Physiol Pharmacol 1966;44:115-28.
5. Chang TMS. Semipermeable aqueous microcapsules ("artificial cells"): With emphasis on experiments in an extracorporeal shunt system. Trans Am Soc Artif Intern Organs 1966;12: 13-9.
6. Chang TMS. Artificial cells. Springfield, Illinois: C.C. Thomas, 1972.
7. Chang TMS. Microencapsulated adsorbent hemoperfusion for uremia, intoxication and hepatic failure. Kidney Int 1975; 7:5387-92.
8. Winchester JF. Hemoperfusion. In: Mäher JF, ed. Replacement of renal function by dialysis. Boston: Kluwer Academic Publisher, 1988:439-592.
9. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980;210:908-9.
10. Soon-Shiong P, Otterlie M, Skjak-Braek G, Smidsrod O, Heintz R, Lanza RP, Espevik T. An immunologie basis for the fibrotic reaction to implanted microcapsules. Transplant Proc 1991;23:758-9.
11. Wong H, Chang TMS. Bioartificial liver: Implanted artificial cells microencapsulated living hepatocytes increases survis'al of liver failure rats. Int J Artif Organs 1986;9:335.
12. Bruni S, Chang TMS. Hepatocytes immobilized by microencapsulation in artificial cells: Effects on hyperbilirubinemia in Gunn rats.y Biomater Artif Cells Artif Organs 1989;17:403-12.
13. Dixit V, Darvasi R, Arthur M, Brezina M, Lewin K, Gitnick G. Restoration of liver function in Gunn rats without immunosuppression using transplanted microencapsulated hepatocytes. Hepatol 1990;12:1342-9.
14. Goosen M, ed. Fundamentals of animal cell encapsulation and immobilization. Boca Raton, Florida: CRC Press, 1992.
15. Chang TMS. Artificial cells. In: Dulbecco R, ed. Encyclopedia of human biology 1997;l:457-63.
16. Chang TMS. Artificial cells with emphasis on bioencapsulation in biotechnology. Biolechnol Ann Rev 1995;l:267-95.
17. Lanza RP, Cooper DKC. Xenotransplantation of cells and tissues: Application to a range of diseases, from diabetes to Alzheimer's. Mole Med Today 1998;4:39-45.
18. Prokop A, Hunkeler D, Cherrington AD, eds. Bioartificial organs: Science, medicine and technology. Ann NY Acad Sei 1977;831:174.
19. Chang TMS, Prakash S. Therapeutic uses of microencapsulated genetically engineered cells. Mole Med Today 1998;4: 221-7.
20. Aebischer P, Pochan NA, Heyd B, De Tribolet N. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 1996; 1:851-60.
21. Basic D, Vacek I, Sun AM. Microencapsulation and transplantation of genetically engineered cells: A new approach to somatic gene therapy. Artif Cells Blood Sitbstit Immobil Biolechnol 1996;24:219-55.
22. Saitoh Y, Taki H, Arita N, Hayakawa T. Cell therapy with encapsulated xenogeneic tumor cells secreting betaendorphin for treatment of peripheral pain. Cell Transplant 1995;l(Suppl.):S13-7.
23. Okada N, Miyamoto H, Mayumi T. Cytomedical therapy for IgGl plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginatepoly(L)lysine-alginate membrane. Biocliim Biophys Acta 1997; 1360:53-63.
24. Hendy AI, Hortelano G, Tannenbaum GS, Chang PL. Growth retardation-an unexpected outcome from growth hormone gene therapy in normal mice with microencapsulated myoblasts. Hum Gene Ther 1966;7:61-70.
25. Date I, Ohmoto T, Emeride DF. Chromaffin cell survival from both young and old donors is enhanced by co-grafts of polymer-encapsulated human NGF-secreting cells. Neurorepon 1996;7:1813-8.
26. Winn SR, Hammang JP, Baetga EE. Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons. Proc Natl Acad Sei USA 1994:91(6):2324.
27. Aebischer P, Schluep M, Baetga EE. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996;2:696-9.
28. Coromili V, Chang TMS. Polydisperse dextran as a diffusing test solute to study the membrane permeability of alginate polylysine microcapsules. Biomater Artif Cells Immobilization Biotech 1993;21:427-44.
29. Colton CK. Implantable biohybrid artificial organs. Cell Transplant 1996;4:415-36.
30. Friedman EA. Bowel as an artificial kidney. Am J Kidney Dis 1996;28:521-S.
31. Prakash S, Chang TMS. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in urémie rats. Nature Med 1996;2(8):883-7.
32. Chang TMS, Prakash S. Artificial cells and genetically engineered microencapsulated for E. coli cells, for urea and ammonia removal. In: Tuar RS, ed. Methods in molecular biology. Expression and Detection of Recombinant Gene Series. Totowa, New Jersey: Humana Press, 1996:343-57.
33. Prakash S, Chang TMS. Preparation and in-vitro analysis of engineered E. coli DH5 cells, microencapsulated in artificial cells for urea and ammonia removal. Bioteclmol Bioengin 1995;46:621-6.
34. Prakash S, Chang TMS. Growth and survival of renal failure rats that received oral microencapsulated genetically engineered E. coli DH5 cells for urea removal. Biomater Artif Cells Immobilization Biotechnol 199S;26:35-51.
35. Wrong OM, Edmonds CI, Chadwick VS. The large intestine. Lancaster: MTP Press, 1981.
36. Chang TMS, Poznansky MJ. Semipermeable microcapsules containing catalase for enzyme replacement in acatalsaemic mice. Nature 1968;218(5138):242-5.
37. Chang TMS. The in vivo effects of semipermeable microcapsules containing L-asparaginase on 6C3HED lymphosarcoma. Nature 1971;229(528);117-8.
38. Bourget L, Chang TMS. Phenylalanine ammonia-lyase immobilized in microcapsules for the depleture of phenylalanine in plasma in phenylketonuric rat model. Biochim Biophys Acta 1986;883:432-8.
39. Chang TMS, Bourget L, Lister C. New theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. Artif Cells Blood Snbstit Immobil Biotechnol 1995;25:l-23.
40. Palmour RM, Goodyer P, Reade T, Chang TMS. Microencapsulated xanthine oxidase as experimental therapy in Lesch-Nyhan Disease. Lancet 1989;2(8664):687-8.
41. Savitsky JP, Doozi J, Black J, Arnold JD. A clinical safety trial of stroma free hemoglobin. Clin Pharm Ther 1978;23:73.
42. Chang TMS. Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde. Biochem Biophys Res Commun 1971;44: 1531-3.
43. Chang TMS. Blood substitutes: Principles, methods, products and clinical trials. Vol. I. Basel: Karger, 1997.
44. Benesch R, Benesch RE, Yung S, Edalji R. Hemoglobin covalently bridged across the polyphosphate binding site. Biochem Biophys Res Commun 1975;63:1123.
45. Gould SA, Moore FA, Moss GS. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma Injury Infect Crit Care 1997;43:325-32.
46. Gould SA, Sehgal LR, Sehgal HL, DeWoskin R, Moss GS. The clinical development of human polymerized hemoglobin. In: Chang TMS, ed. Blood substitutes: Principles, methods, products and clinical trials. Vol. 2. Basel: Karger, 1998:12-28.
47. Pearce LB, Gawryl MS. Overview of preclinical and clinical efficacy of Biopure's HBOCs. In: Chang TMS, ed. Blood substitutes: Principles, methods, products and clinical trials. Vol. 2. Basel: Karger, 1998:82-98.
48. Hsia JC. o-Raffmose polymerized hemoglobin as red blood cell substitute. Biomater Artif Cells Immobilization Biotechnol 1991;19:402.
49. Adamson JG, Moore C. Hemolink, an o-raffinose crosslinked hemoglobin-based oxygen carrier. In: Chang TMS, ed. Blood substitutes: Principles, methods, products and clinical trials. Vol. 2. Basel: Karger, 1998:62-79.
50. Bunn HF, Jandl JH. The renal handling of hemoglobin. Trans Assoc Am Physicians 1968;81:147.
51. Walder JA, Zaugg RH, Walder RY, Steele JM, Klotz IM. Diaspirins that crosslink alpha chains of hemoglobin: bis(3,5dibromosalicyl)succinate and bis(3,5dibromosalicyl) fumarate. Biochemistry 1979;18:4265-70.
52. Nelson DJ. Blood and HemAssist (DCLHb): Potentially a complementary therapeutic team. In: Chang TMS, ed. Blood substitutes: Principles, methods, products and clinical trials. Vol. 2. Basel: Karger, 1998:39-57.
53. Wong JT. Rightshifted dextran hemoglobin as blood substitute. Biomat Artif Cells Artif Organs 1998;16:237-45.
54. Iwashita Y, Yabuki A, Yamaji K, Iwasaki K, Okami T, Irati C, Kosaka K. A new resuscitation fluid "stabilized hemoglobin" preparation and characteristics. Biomat Artif Cells Artif Organs 1988;16:271-SO.
55. Shorr RG, Viau AT, Abuchowski A. A Phase IB safety evaluation of PEG hemoglobin as an adjuvant to radiation therapy in human cancer patients (Abstract). Artif Cells Blood Substit Immobilization Biolechnol 1996;24:407.
56. Huffman SJ, Looker DL, Roehrich JM. Expression of fully functional tetrameric human hemoglobin in Eschericliia coll Proc Natl Acad Sei USA 1990;87:8521-5.
57. Freytag JW, Templeton D. Optra. In: Rudolph AS, Rabinovici R, Feuerstein GZ, eds. Red cell substitutes: Basic principles and clinical application. New York: Marcel Dekker, 1997:325-34.
58. Winslow RM, Vandegriff M, Intaglietta M, eds. Blood substitutes. Boston: Birkhäuser, 1996.
59. Chang TMS, D'Agnillo F, Razack S. A second generation hemoglobin based blood substitute with antioxidant activities. In: Chang TMS, ed. Blood substitutes: Principles, methods, products and clinical trials. Vol. 2. Basel: Karger, 1998:178-86.
60. Djordjevich L, Miller IF. Synthetic erythrocytes from lipid encapsulated hemoglobin. Exp Hematol 1980;8:584.
61. Rudolph AS, Rabinovici R, Feuerstein GZ, eds. Red blood cell substitutes. New York: Marcel Dekker, 1997.
62. Tsuchida E, eds., Artificial red cells. New York: John Wiley & Sons, 1995.
63. Chang TMS, Yu WP. Nanoencapsulation of hemoglobin and red blood cell enzymes based on nanotechnology and biodegradable polymer. In: Chang TMS, ed. Blood substitutes: Principles, methods, products and clinical trials. Vol. 2. Basel: Karger, 1998:216-23.